Regulus Therapeutics Inc. (RGLS) Shares Down 3.4%
Regulus Therapeutics Inc. (NASDAQ:RGLS)’s share price dropped 3.4% during mid-day trading on Wednesday . The company traded as low as $3.11 and last traded at $3.14, with a volume of 171,016 shares traded. The stock had previously closed at $3.25.
RGLS has been the subject of a number of research analyst reports. Needham & Company LLC restated a “buy” rating on shares of Regulus Therapeutics in a research note on Tuesday, May 3rd. Wells Fargo & Co. initiated coverage on Regulus Therapeutics in a research note on Tuesday, May 3rd. They issued a “buy” rating for the company. Zacks Investment Research lowered Regulus Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, May 6th. FBR & Co restated a “buy” rating and issued a $30.00 target price on shares of Regulus Therapeutics in a research note on Thursday, June 2nd. Finally, Chardan Capital raised their target price on Regulus Therapeutics from $15.00 to $20.00 and gave the stock a “buy” rating in a research note on Tuesday, June 7th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Regulus Therapeutics has a consensus rating of “Buy” and an average price target of $10.17.
The company’s 50 day moving average price is $3.49 and its 200-day moving average price is $5.42. The firm’s market cap is $167.44 million.
Regulus Therapeutics (NASDAQ:RGLS) last issued its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by $0.02. On average, equities analysts predict that Regulus Therapeutics Inc. will post ($1.59) earnings per share for the current fiscal year.
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.